Le Lézard3 小时
CStone Partners with SteinCares to Market Sugemalimab in Latin America
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This ...
Medindia3 小时
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment   TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...
Medindia3 小时
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of ...
(9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by ...
来自MSN4 小时
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...
BioArctic: FDA approves IV maintenance dosing of Leqembi (lecanemab-irmb) for the treatment ...
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Le Lézard5 小时
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early ...
BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once ...